Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia

IF 3.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-09-01 DOI:10.1016/j.clinthera.2025.05.016

Hans Kristian Råket MD PhD , Tamara Milder MBBS MMed FRACP PhD , Melisa Litchfield MSc , Camilla Bjørn Jensen PhD , Joanna Nan Wang MD , Espen Jimenez-Solem MD PhD , Janne Petersen PhD , Sallie-Anne Pearson PhD , Adam Jaffe MD FRCP FRCPCH FRACP , Michael O. Falster PhD

{"title":"Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia","authors":"Hans Kristian Råket MD PhD , Tamara Milder MBBS MMed FRACP PhD , Melisa Litchfield MSc , Camilla Bjørn Jensen PhD , Joanna Nan Wang MD , Espen Jimenez-Solem MD PhD , Janne Petersen PhD , Sallie-Anne Pearson PhD , Adam Jaffe MD FRCP FRCPCH FRACP , Michael O. Falster PhD","doi":"10.1016/j.clinthera.2025.05.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Elexacaftor/tezacaftor/ivacaftor (ETI) is an efficacious targeted therapy for cystic fibrosis, but its impact on the use of maintenance therapies has not been assessed in Australia.</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study including individuals with at least 1 ETI dispensing. Quarterly prevalence of airway therapies, antibiotics, and gastrointestinal and endocrine medications was evaluated 24 months before and after ETI initiation. Odds ratios for dispensing were estimated using mixed-effects logistic regression.</div></div><div><h3>Findings</h3><div>Airway therapies and oral/inhaled antibiotic use declined after ETI, whereas gastrointestinal and endocrine therapies remained stable.</div></div><div><h3>Implications</h3><div>Elexacaftor/tezacaftor/ivacaftor is associated with a reduced treatment burden in cystic fibrosis, supporting broader access.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 9","pages":"Pages 813-815"},"PeriodicalIF":3.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825001845","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Elexacaftor/tezacaftor/ivacaftor (ETI) is an efficacious targeted therapy for cystic fibrosis, but its impact on the use of maintenance therapies has not been assessed in Australia.

Methods

We performed a retrospective cohort study including individuals with at least 1 ETI dispensing. Quarterly prevalence of airway therapies, antibiotics, and gastrointestinal and endocrine medications was evaluated 24 months before and after ETI initiation. Odds ratios for dispensing were estimated using mixed-effects logistic regression.

Findings

Airway therapies and oral/inhaled antibiotic use declined after ETI, whereas gastrointestinal and endocrine therapies remained stable.

Implications

Elexacaftor/tezacaftor/ivacaftor is associated with a reduced treatment burden in cystic fibrosis, supporting broader access.

查看原文本刊更多论文

在澳大利亚，开始使用Elexacaftor/Tezacaftor/Ivacaftor后囊性纤维化患者维持治疗的使用减少

目的：Elexacaftor/tezacaftor/ivacaftor （ETI）是一种有效的囊性纤维化靶向治疗，但其对维持治疗使用的影响尚未在澳大利亚进行评估。方法：我们进行了一项回顾性队列研究，包括至少1次ETI分配的个体。在ETI开始前后24个月，评估每季度气道治疗、抗生素、胃肠道和内分泌药物的流行情况。使用混合效应逻辑回归估计配药的优势比。结果：气道治疗和口服/吸入抗生素的使用在ETI后下降，而胃肠道和内分泌治疗保持稳定。结论：Elexacaftor/tezacaftor/ivacaftor可减轻囊性纤维化患者的治疗负担，支持更广泛的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.